ICU Medical, Incorporated (NASDAQ:ICUI) Director George A. Lopez bought 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 15th. The stock was bought at an average cost of $155.60 per share, for a total transaction of $1,867,200.00. Following the completion of the acquisition, the director now owns 577,716 shares in the company, valued at approximately $89,892,609.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of ICU Medical, Incorporated (NASDAQ:ICUI) opened at 158.10 on Tuesday. The firm’s 50-day moving average price is $147.87 and its 200-day moving average price is $141.33. ICU Medical, Incorporated has a 12-month low of $94.28 and a 12-month high of $159.05. The company has a market capitalization of $2.58 billion, a PE ratio of 43.20 and a beta of 0.33.
ICU Medical, (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, March 1st. The company reported $1.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.19 by $0.01. ICU Medical, had a return on equity of 10.70% and a net margin of 15.18%. The business earned $95.70 million during the quarter, compared to analyst estimates of $94.43 million. During the same period in the previous year, the firm earned $0.96 EPS. ICU Medical,’s quarterly revenue was up 5.9% compared to the same quarter last year. On average, analysts expect that ICU Medical, Incorporated will post $3.73 EPS for the current fiscal year.
Your IP Address:
Several institutional investors have recently modified their holdings of the stock. Janus Capital Management LLC raised its position in shares of ICU Medical, by 276.1% in the fourth quarter. Janus Capital Management LLC now owns 516,469 shares of the company’s stock valued at $76,108,000 after buying an additional 379,132 shares in the last quarter. Norges Bank acquired a new position in shares of ICU Medical, during the fourth quarter valued at about $18,127,000. Royal Bank of Canada raised its position in shares of ICU Medical, by 57.2% in the second quarter. Royal Bank of Canada now owns 207,226 shares of the company’s stock valued at $23,365,000 after buying an additional 75,396 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of ICU Medical, by 8.0% in the third quarter. BlackRock Fund Advisors now owns 1,006,142 shares of the company’s stock valued at $127,156,000 after buying an additional 74,697 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of ICU Medical, by 22.6% in the third quarter. JPMorgan Chase & Co. now owns 380,059 shares of the company’s stock valued at $48,032,000 after buying an additional 70,061 shares in the last quarter. Institutional investors and hedge funds own 88.72% of the company’s stock.
Separately, Zacks Investment Research raised ICU Medical, from a “hold” rating to a “buy” rating and set a $163.00 target price on the stock in a report on Monday, January 2nd.
About ICU Medical,
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.